Oxford BioMedica PLC (OXBDF)

[marcusl2]

HIV controlled with improved CAR T therapy; human testing planned next spring.

The improved therapy is planned for testing in a few patients beginning in the late spring of 2018, Riley said. It benefits from the work of scientists including University of Pennsylvania researcher Carl June, whose research led to the leukemia treatment, Kymriah, he said.

“It was really a very thorough investigation, and very timely,” Johnston said. “It looked at a lot of the critical components of how we’re going to apply CAR T cell therapy in HIV.”

HTTP://www.sandiegouniontribune.com/business/biotech/sd-me-immune-hiv-20171012-story.html